THE ALT/LAB · Controlled Lab Entry — · —
THE ALT/LAB
research compounds · united states
Research-Use Verification

All products sold on this website are research-grade materials intended exclusively for laboratory research use by qualified professionals and are not approved for human or veterinary use.

These products are not drugs, foods, cosmetics, or dietary supplements, have not been evaluated by the FDA, and are not intended for human or animal use. Any personal, human, animal, or other non-research use is strictly prohibited.

The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.

I confirm I am twenty-one (21) years of age or older and a qualified researcher or institutional buyer acquiring these materials for in vitro research only.
I understand these products are for research use only, are not for human or veterinary use, have not been evaluated by the FDA, and I will not administer them to any person, including myself.
— Decline & Exit —
est. United States · 2026 File No. AL/2026/ENTRY-001 For research use only
Free 2-Day shipping on US orders $200+
manufactured in the USA Sterile lyophilised ≥99% purity · HPLC verified for research use only · not for human use
THE ALT/LAB UNITED STATES
(0)
CJC + IPA NO DAC 5+5 THE ALT/LABCJC + IPA NO DAC 5+5For Research Use Only
Not For Human ConsumptionCompounded · USA
research compound · for research use only · gh secretagogues research

CJC + IPA NO DAC 5+5

$115.00
Quantity pricing3+ · 3% off5+ · 5% off10+ · 10% off15+ · 15% off

CJC-1295 no DAC 5mg + Ipamorelin 5mg per vial · Research use only

View COA →

Specification

identity · literature · handling

Modified GRF(1-29) (no DAC) + GH secretagogue blend.

  • CJC-1295 no DAC 10mg — Modified GRF(1-29), no DAC.
  • Ipamorelin 10mg — Pentapeptide GH secretagogue.

Identity
Purity: ≥99% (HPLC)
Form: sterile lyophilised powder
Presentation: 3 mL vial

Research literature
This blend combines modified GRF(1-29) — the no-DAC CJC-1295 species — with ipamorelin, a selective pentapeptide growth-hormone secretagogue. Foundational research on the CJC-1295 albumin-conjugate platform in rat anterior pituitary cells investigates GRF-receptor activation and in-vitro stability, while research on ipamorelin in rat pituitary cultures and pentobarbital-anaesthetised rats characterises its potency and selectivity at the GHS-R1a receptor relative to GHRP-6. The two peptides are studied as complementary research tools for examining somatotroph signalling.

References

  1. Jetté L et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. PMID 15817669.
  2. Raun K et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. PMID 9849822.

Documentation
Batch Certificate of Analysis (HPLC, third-party) provided for the lot shipped.

Handling (research)
Store lyophilised cold and protected from light. Reconstitute according to the researcher’s own laboratory procedure.

For Research Use Only. Not for Human or Veterinary Use. Not a drug, food, or supplement; not evaluated by the FDA; not intended for human or animal use.